Tafluprost
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Tafluprost: From Open-Angle Glaucoma to Primary Hereditary Glaucoma
One-Sentence Summary
Tafluprost is a prostaglandin F2α (FP receptor) agonist eye drop, originally used to treat open-angle glaucoma and ocular hypertension. The TxGNN model predicts it may be useful for primary hereditary glaucoma, but this is a model prediction only, with 0 clinical trials and 0 publications currently supporting this specific indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Open-angle glaucoma; ocular hypertension |
| Predicted New Indication | Primary hereditary glaucoma |
| TxGNN Prediction Score | 98.62% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the compiled sources. Based on the drug class, tafluprost is a prostaglandin F2α analogue. It acts on the FP receptor (its active metabolite, tafluprost acid, has an EC50 of 0.53 nM at the human FP receptor) and lowers intraocular pressure (IOP) by increasing uveoscleral outflow.
Primary hereditary glaucoma (for example, primary congenital glaucoma) is also an IOP-driven disease, so the mechanism is plausible and the high score is consistent with the approved glaucoma indication.
There are important caveats. No trials or literature were found for the hereditary or congenital forms. Developmental angle-anomaly forms may respond poorly to outflow-based therapy. Paediatric safety and efficacy have not been established.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for primary hereditary glaucoma.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13872P | Taflotan Ophthalmic Solution 0.0015% | Sterile solution | Not specified in the registration data |
| SIN14856P | Taflotan-S Ophthalmic Solution 0.0015% | Sterile solution | Not specified in the registration data |
| SIN15060P | Tapcom-S Ophthalmic Solution | Sterile solution | Not specified in the registration data |
Safety Considerations
- Drug Interactions: The interaction query completed with one pharmacology entry only: tafluprost's target is the FP receptor (gene PTGFR). No drug-drug interactions were identified.
- Class-related observations (from the literature on other predicted indications, not from label text): conjunctival hyperaemia is a known adverse effect of prostaglandin analogues, and a pharmacovigilance analysis reported an association between topical PGF2α analogues and blood pressure elevation.
Please refer to the package insert for key warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score and a plausible class mechanism (IOP lowering). No trials or publications address hereditary or congenital glaucoma, and paediatric safety and efficacy are unestablished. Developmental forms may also respond poorly to outflow-based therapy.
To proceed, the following is needed:
- Clinical and literature evidence in primary hereditary/congenital glaucoma, including paediatric data
- Package insert warnings and contraindications from HSA
- Confirmed mechanism of action data (DrugBank)
- Review of the approved indication wording for the three Singapore registrations
Other predicted indications (ranks 2–10): None is recommended to proceed. The remaining predictions (visceral calciphylaxis, tinea nigra, the three thoracic outlet syndromes, angiodysplasia of stomach, spontaneous coronary artery dissection, lymphangiectasis) have no supporting trials or literature and no plausible mechanism, and topical ocular dosing gives minimal systemic exposure. They look like graph artefacts. "Vascular disease" (rank 9) has nine publications, but these cover ocular vascular and tolerability effects, not treatment, and one reports a blood pressure safety signal. All are Hold.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.